Cargando…
Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays
BACKGROUND: Amyloid-β 1–42 (Aβ(1–42)) peptide is a well-established cerebrospinal fluid (CSF) biomarker for Alzheimer’s disease (AD). Reduced levels of Aβ(1–42) are indicative of AD, but significant variation in the absolute concentrations of this analyte has been described for both healthy and dise...
Autores principales: | Schauer, Stephen P., Mylott, William R., Yuan, Moucun, Jenkins, Rand G., Rodney Mathews, W., Honigberg, Lee A., Wildsmith, Kristin R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264029/ https://www.ncbi.nlm.nih.gov/pubmed/30486870 http://dx.doi.org/10.1186/s13195-018-0445-0 |
Ejemplares similares
-
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics
por: Wildsmith, Kristin R, et al.
Publicado: (2014) -
Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021) -
Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2
por: Faria, Morse, et al.
Publicado: (2019) -
Preanalytical requirements of urinalysis
por: Delanghe, Joris, et al.
Publicado: (2014) -
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)
por: Salloway, Stephen, et al.
Publicado: (2018)